Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05415358 · ClinicalTrials.gov registry record
Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients
A clinical trial of Lung Cancer, Non-Small Cell, sponsored by Wake Forest University Health Sciences.
- Active
- Registry status
- 23
- Enrollment target
- 2
- Study locations
NCT05415358: Active study of Lung Cancer, Non-Small Cell, sponsored by Wake Forest University Health Sciences.
NCT05415358 is a study of Lung Cancer, Non-Small Cell that is active but no longer recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 23 participants, below the 454-participant average among 16 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05415358, a study of Lung Cancer, Non-Small Cell, is active but no longer recruiting, sponsored by Wake Forest University Health Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- 23 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to examine the association between ctDNA/immune biomarkers and disease progression in patients who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of immune checkpoint inhibitor monotherapy or immune checkpoint inhibitor combination chemotherapy for mNSCLC.
Primary Outcome
Disease progression status determined by the treating investigator per standard care
Conditions Studied
Interventions
- OTHER Blood and tissue samples
Study Locations (2)
North Carolina
- Atrium Health Levine Cancer - Charlotte
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2035-09 |
What the registry record for NCT05415358 still lists
NCT05415358 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 454-participant average among 16 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Lung Cancer, Non-Small Cell appearing as the primary indexed condition, and to 1 intervention - of which Blood and tissue samples is the first listed.
NCT05415358 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05415358 about?
NCT05415358 is a clinical study titled "Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients". The purpose of this study is to examine the association between ctDNA/immune biomarkers and disease progression in patients who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of immune checkpoint inhibitor monotherapy or immune checkpoint inhibitor combinat...
What is the current status of trial NCT05415358?
This trial is currently active not recruiting. The enrollment target is 23 participants. The study started on 2023-01-17. Estimated completion is 2035-09.
What conditions does trial NCT05415358 study?
This clinical trial studies the following conditions: Lung Cancer, Non-Small Cell.
What interventions are being tested in trial NCT05415358?
The interventions under investigation include: Blood and tissue samples (OTHER).
Who is sponsoring clinical trial NCT05415358?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05415358 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer, Non-Small Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05415358's enrollment target sits among peer trials
23 15th of 16 higher than 2 of 16 other Lung Cancer, Non-Small Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer, Non-Small Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Engagement of Veterans With Lung Cancer
RECRUITING · NA
-
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
-
Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
RECRUITING
-
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
RECRUITING · Phase 1
-
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
RECRUITING
-
A Multicenter Cancer Biospecimen Collection Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI